Reshape Lifesciences Inc. (RSLS) SEC Filing 8-K Material Event for the period ending Wednesday, August 22, 2018

Reshape Lifesciences Inc.

CIK: 1371217 Ticker: RSLS

View differences made from one to another to evaluate Reshape Lifesciences Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Reshape Lifesciences Inc..


Assess how Reshape Lifesciences Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Reshape Lifesciences Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: RSLS
CIK: 1371217
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-053941
Submitted to the SEC: Tue Aug 28 2018 4:05:45 PM EST
Accepted by the SEC: Tue Aug 28 2018
Period: Wednesday, August 22, 2018
Industry: Electromedical And Electrotherapeutic Apparatus
  1. Listing Status

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: